News

N-Bromosuccinimide (NBS, CAS 128-08-5) remains one of the most widely used mild selective brominating reagents in modern organic synthesis, and its global market continues steady growth, driven by expanding drug pipelines and agrochemical R&D programs.

Unlike elemental bromine, NBS enables controlled allylic, benzylic and α-carbonyl bromination with lower over-bromination risk and safer handling, making it the preferred option for Wohl-Ziegler reactions in medicinal chemistry. Industry reports indicate that pharma-grade NBS with 99% purity is the fastest-growing segment, as API manufacturers tighten impurity specifications for GMP-aligned synthesis routes.

Supply volatility remains a key challenge: NBS production is tightly linked to bromine feedstock cycles, and REACH, TSCA and hazardous goods transport rules raise compliance barriers for cross-border shipments. Many global chemical buyers are locking in long-term supplier partnerships to mitigate price and lead-time fluctuations.

Our 99% N-Bromosuccinimide meets synthesis-grade specifications, with pre-shipment quality testing. Samples, bulk orders and full export compliance packages are open for inquiry.